Literature DB >> 3598464

Platelet-mediated cytotoxicity. Role of antibody and C3, and localization of the cytotoxic system in membranes.

S Slezak, D E Symer, H S Shin.   

Abstract

Platelets are one of several cell types capable of mediating antibody-dependent cellular cytotoxicity. We have developed a plasma-free system in which washed mouse platelets lyse washed antibody and complement-sensitized SRBC targets in the presence of EDTA. The dose-response curve is concave to the abscissa, indicating that lysis is a one-hit reaction. Determination of the actual number of platelets required to lyse a target shows that each platelet could lyse a single target. A limited degree of lysis is observed when platelets are incubated with SRBC sensitized with monoclonal IgG2a alone, but no lysis occurs with SRBC bearing comparable amounts of other isotypes. In the presence of C1 through C3, but not C1 through C2, efficient lysis is triggered by complement-fixing monoclonal IgG2a, IgG2b, and IgG3. In contrast, IgM and non-complement-fixing IgG1 and IgE are inactive. To achieve efficient lysis, it appears that platelets require both target cell-bound antibody and C3 fragments in close proximity. It is unlikely that proteases, pore-forming proteins, or toxic oxygen metabolites are involved in platelet-mediated lysis. Freezing and thawing of platelets, sonication, or sonication followed by hypotonic shock causes severe depletion of cytoplasmic and granular contents, as shown by electron microscopy and marker assays. However, the membrane fraction of these preparations retains cytolytic activity. When platelets are treated with trypsin or heated, lytic activity is eliminated, indicating that at least one component of this system is protein. These findings, as well as the fact that platelets do not lyse unsensitized innocent bystander SRBC, suggest that the complete cytotoxic system of platelets capable of specific recognition and lysis resides in their membranes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598464      PMCID: PMC2189603          DOI: 10.1084/jem.166.2.489

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  Platelet 5-HT uptake and release stopped rapidly by formaldehyde.

Authors:  J L Costa; D L Murphy
Journal:  Nature       Date:  1975-05-29       Impact factor: 49.962

2.  Immune mechanisms in homotransplantation. I. The role of serum antibody and complement in the neutralization of lymphoma cells.

Authors:  H J WINN
Journal:  J Immunol       Date:  1960-05       Impact factor: 5.422

Review 3.  Mechanisms of tumor immunity: the role of antibody and nonimmune effectors.

Authors:  H S Shin; R J Johnson; G R Pasternack; J S Economou
Journal:  Prog Allergy       Date:  1978

Review 4.  Antibody-dependent cell-mediated cytolysis (ADCC): analyses and projections.

Authors:  J C Lovchik; R Hong
Journal:  Prog Allergy       Date:  1977

5.  Isolation of myelin from nerve tissue.

Authors:  W T Norton
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

6.  Antibody-mediated suppression of tumor growth. II. Macrophage and platelet cooperation with murine IgG1 isolated from alloantiserum.

Authors:  R J Johnson; G R Pasternack; H S Shin
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

7.  Antibody-mediated suppression of lymphoma: participation of platelets, lymphocytes, and nonphagocytic macrophages.

Authors:  H S Shin; M L Hayden; C L Gately
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

8.  Effector mechanisms of cytolytically activated macrophages. I. Secretion of neutral proteases and effect of protease inhibitors.

Authors:  D O Adams
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

9.  Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.

Authors:  H S Shin; M Hayden; S Langley; N Kaliss; M R Smith
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

10.  Binding of monomeric immunoglobulins to Fc receptors of mouse macrophages.

Authors:  J C Unkeless; H N Eisen
Journal:  J Exp Med       Date:  1975-12-01       Impact factor: 14.307

View more
  8 in total

1.  Cells within the vascular system capable of mediating trypanocidal activity in vitro.

Authors:  K T Shaw; Y Mawji; M M Stevenson; P A Kongshavn
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

2.  Human platelet inhibition of Toxoplasma gondii growth.

Authors:  B F Chumpitazi; J Simon; B Polack; F Peyron; S Picot; J Ricard; P Ambroise-Thomas
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Platelet-complement interactions in mesangial proliferative nephritis in the rat.

Authors:  R J Johnson; P Pritzl; H Iida; C E Alpers
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

4.  Human platelets modulate edema formation in isolated rabbit lungs.

Authors:  J E Heffner; J A Cook; P V Halushka
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

5.  Platelets mediate neutrophil-dependent immune complex nephritis in the rat.

Authors:  R J Johnson; C E Alpers; P Pritzl; M Schulze; P Baker; C Pruchno; W G Couser
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

6.  Human platelets effectively kill K-562 cells, a chronic myelogenic leukemia cell line, in vitro.

Authors:  T Sagawa; T Kodama; A Tominaga; M Okada
Journal:  Jpn J Cancer Res       Date:  1990-05

7.  Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane.

Authors:  E C Yong; E Y Chi; T R Fritsche; W R Henderson
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

8.  A requirement for membrane-associated phospholipase A2 in platelet cytotoxicity activated by receptors for immunoglobulin G and complement.

Authors:  D E Symer; W A Paznekas; H S Shin
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.